-
Your selected country is
Brazil
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- For U.S. patents that may apply, see bd.com/patents.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- An isotype control should be used at the same concentration as the antibody of interest.
- Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
- Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
- Tandem fluorochromes contain both an energy donor and an energy acceptor. Although every effort is made to minimize the lot-to-lot variation in the efficiency of the fluorochrome energy transfer, differences in the residual emission from the donor may be observed. Additionally, multi-laser cytometers may directly excite both the donor and acceptor fluorochromes. Therefore, we recommend for every tandem conjugate, a matched individual single-stain control be acquired for generating a compensation or spectral unmixing matrix.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
Companion Products
The 16A1 monoclonal antibody specifically recognizes human CD140a which is also known as human platelet derived growth factor receptor α (PDGFRα). CD140a (PDGFRα) is an ~170 kDa single pass type I transmembrane glycoprotein that is encoded by PDGFRA (platelet derived growth factor receptor alpha) which belongs to the receptor tyrosine kinase (RTK) class III family. This receptor is comprised of an N-terminal extracellular domain with five IgC2-like domains, and a transmembrane sequence followed by a cytoplasmic region with a split tyrosine kinase domain. CD140a (PDGFRα) is expressed on a variety of cell types including platelets, monocytes, fibroblasts, endothelial cells, smooth muscle cells, glial cells, chondrocytes as well as numerous tumor cell types. PDGFRα dimerizes and autophosphorylates when binding to homodimeric or heterodimeric platelet-derived growth factors (PDGF) comprised of disulfide-bonded A, B, or C (but not D) isoforms, ie, PDGF-AA, PDGF-AB, PDGF-BB, and PDGF-CC. PDGFRα can also heterodimerize with platelet derived growth factor receptor β (PDGFRβ, also known as CD140b) and autophosphorylate upon binding to PDGF-AB, PDGF-BB, and possibly PDGF-CC and PDGF-DD. Homodimerized CD140b (PDGFRβ) is activated by PDGF-BB and PDGF-DD. PDGF ligands stimulate the growth, proliferation, migration, and survival of PDGF Receptor-positive normal cells as well as tumor cells. CD140a (PDGFRα) plays key roles in multiple processes including embryonic development, wound healing, and the regulation of platelet activation.
Development References (4)
-
Demoulin JB, Essaghir A. PDGF receptor signaling networks in normal and cancer cells.. Cytokine Growth Factor Rev. 2014; 25(3):273-83. (Biology). View Reference
-
Hara Y, Yamashita T, Oishi N, et al. TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting microenvironmental platelet-derived growth factor signaling.. Anticancer Res. 2015; 35(3):1423-31. (Clone-specific: Flow cytometry). View Reference
-
Hart CE, Bowen-Pope DF. CD140a and b (PDGRα and β) Workshop Panel report. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:739-741.
-
Miyazaki S, Sugawara H, Tamura T. Cross-lineage (Blind Panel) study and human leucocyte differentiation antigen database. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:3-20.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.